ANCA ASSOCIATED VASCULITIS
Clinical trials for ANCA ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANCA ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on lupus and scleroderma in new trial
Disease control TerminatedThis early-stage study is testing a new treatment called RD06-04, which uses a patient's own immune cells modified to target and attack faulty B cells. The goal is to see if it is safe and tolerable for people with active autoimmune diseases like lupus, scleroderma, and Sjögren's…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 07:01 UTC
-
Immune reset: CAR T-Cells take on lupus and other autoimmune diseases
Disease control OngoingThis early-phase study tests a one-time treatment called KYV-101, which uses a patient's own modified immune cells to target and destroy faulty B cells that drive autoimmune diseases like lupus, vasculitis, and scleroderma. Up to 24 adults will receive the therapy and be monitore…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
CAR-T therapy for autoimmune diseases: trial pulled before start
Disease control TerminatedThis early-phase trial aimed to test a CD19-targeted CAR-T cell therapy (RD06-04) in people with autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis. The goal was to see if the treatment was safe and could reduce disease activity. However, the study was with…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:20 UTC